论文部分内容阅读
ＧｌａｘｏＷｅｌｌｃｏｍｅ公司已提出其抗流感病毒药ｚａｎａｍｉｖｉｒ（Ｒｅｌｅｎｚａ）的上市申请，该药在两项Ⅲ期临床试验中均显示对流感具有治疗和预防作用。在一项有４５５名受试者参加的研究中，患者在感冒症状发作后３６小时内开始用药，连续５天，每日２次吸入ｚ
GlaxoWellcome has filed a listing of its anti-influenza virus zanamivir (Relenza), which has been shown to have a therapeutic and prophylactic effect on influenza in both Phase III clinical trials. In a study of 455 participants, patients started medication within 36 hours of the onset of a cold symptom and inhaled twice daily for 5 days